Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Cempra, Inc. ("Cempra" or the "Company") (Nasdaq: CEMP). Investors who purchased or otherwise acquired shares between May 1, 2016 and November 1, 2016 inclusive (the "Class Period"), are encouraged to contact the Firm by the January 3, 2017 lead plaintiff motion deadline. If you purchased shares of Cempra during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org. There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member. The Complaint alleges that during the Class Period, Cempra made false and/or misleading statements and/or failed to disclose that solithromycin posed significant safety risks for hepatotoxicity, so the Company's public statements were materially false and misleading at all relevant times. On November 2, 2016, the U.S. Food and Drug Administration posted a preliminary review on its website of Cempra's drug, solithromycin, highlighting a significant safety signal for hepatotoxicity. When this information was disclosed to the public, shares of Cempra declined in value, causing investors harm. If you wish to learn more about this lawsuit at no charge to you, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at email@example.com.